How do you weigh the risks and benefits of GLP-1 RAs in patients over age 65 specifically in regards to loss of muscle mass and osteoporosis?
How do you counsel patients about these risks?
This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the upcoming session "GLP1 Agonists in Rheumatic Disease and Osteoarthritis: Should We Give Them to Everyone?" by Dr. C. Thomas Appleton and Dr. @Dr. First Last.
Community PollStarted
Do you offer GLP-1 receptor agonists to patients over age 65?
108 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Sorbonne Université
Answered on
This is indeed a crucial question: rapid weight loss is accompanied not only by a loss of adipose tissue but also by a loss of lean mass, including muscle and bone tissue. This must therefore be taken into account when making decisions, particularly in patients with osteoporosis, frailty, sarcopenic...
Join for free or sign in to see the full answer